Clinical Evidence


The PROLOG Study

The PROLOG (PLGS for Reduction of Low Glucose) study showed a 31% reduction in time spent below 70 mg/dL in patients who used the t:slim X2™ insulin pump with Basal-IQ® technology versus those not using automated insulin suspension. This reduction of time in low glucose occurred without an increase in mean glucose and without rebound hyperglycemia.1

t:slim X2 Insulin Pump with Basal-IQ Technology



Time < 70 mg/dL (%)

*P < 0.001

Time Below 70 mg/dL Graph


Time < 60 mg/dL (%)

*P < 0.001

Time Below 60 mg/dL Graph



Basal-IQ technology reduced time spent low.1



Time < 70 mg/dL at Baseline < 5%

n = 71  |  *P < 0.001

Time Below 70 mg/dL at Baseline Graph


Time < 70 mg/dL at Baseline > 5%

n = 30  |  *P < 0.001

Time Above 70 mg/dL at Baseline Graph



Subjects with more baseline hypoglycemia saw a greater effect.



Time in Range (%)

*P < 0.001

Time in Range Graph


Mean Glucose (mg/dL)

*P = 0.40

Mean Glucose Graph



Overall glycemic control improved while time < 70 mg/dL was minimized.




System Usability

Simple to teach. Simple to learn.

Results from a human factors study conducted to validate the safety of the Basal-IQ user interface demonstrated a 99% success rate among study participants who, after initial training, performed a series of critical tasks using the PLGS system. Out of 530 tasks performed, only seven task failures were observed (defined as needing assistance to complete), none of which were related to safety. The study included users age 6 and older (N = 53), with and without previous insulin pump and/or continuous glucose monitoring (CGM) experience.2

Additionally, most participants in the PROLOG pivotal study, many of whom had no previous experience with pumps or CGM systems, agreed or strongly agreed that the system was simple to learn and use.3



of participants felt very confident using the system.1


thought they would like to use the Basal-IQ system frequently.


thought the Basal-IQ system was simple and easy to use.


did not feel they had to learn a lot to get started with the system.


did not need the support of a technical person to use the system.



Dexcom G6 CGM Technology

Exceptional Accuracy with zero fingersticks*

Dexcom CGM has been shown to reduce median time spent in hypoglycemia by 79% (< 60 mg/dL) at night. In separate clinical trials, Dexcom has demonstrated the sensor accuracy of their continuous glucose monitoring technology in adult and pediatric use, with an overall MARD of 9% for adults and 10% for pediatrics (ages 2-17).‡ 4-5

Advantages of Dexcom G6 CGM

Known for exceptional accuracy and comfort, Dexcom is the preferred CGM brand. Benefits of the Dexcom G6 CGM system include:

  • Zero fingersticks*
  • 10-day sensor wear
  • Simple auto-applicator
  • Acetaminophen blocking§
  • View data on a smart device^
  • Share CGM data with up to ten followers**

The t:slim X2 insulin pump with Basal-IQ technology is the first and only automated insulin delivery system to integrate with this latest technology from Dexcom.


t:slim X2 Insulin Pump with Dexcom G6



Try out the new Basal-IQ feature with our free demo app.

Search for t:simulator™ wherever you purchase apps, or click the badges below to visit the download page.

AppBadge_AppleStore AppBadge_GooglePlay

*If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
†MARD is a statistical measure of accuracy accepted as the industry standard for CGM systems; the lower the number, the better.
‡Historical results based on Dexcom G5 CGM systems.
§G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1,000 mg every six hours. Taking a higher dose may affect the G6 readings.
^For a list of compatible devices, visit The Dexcom G6 CGM transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 pump) and one consumer device (phone or tablet) at the same time.
**Separate Follow App required.

1. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161. doi:10.2337/dc18-0771.
2. Dokken, et al. Usability of a Predictive Low Glucose Suspend (PLGS) Feature on a Touchscreen Insulin Pump. Poster presented at: 17th Annual Diabetes Technology Meeting; November 2-4, 2017; Bethesda, Maryland.
3. Pinsker, et al. Exceptional Usability of Tandem t:slim X2 Insulin Pump with Basal-IQ Predictive Low Glucose Suspend (PLGS): The PROLOG Study. Poster presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
4. Laffel L. Improved Accuracy of Continuous Glucose Monitoring Systems in Pediatric Patients with Diabetes Mellitus: Results from Two Studies. Diabetes Technol Ther. 2016;18(S2). doi:10.1089/dia.2015.0380.
5. Bailey TS, Chang A, Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol. 2015;9(2):209-14. doi: 10.1177/1932296814559746.
6. dQ&A USA Diabetes Connections Surveys, 2013-2018.